Business news for the stock market
Leverkusen (pta033/08.09.2021/18:10) - Leverkusen, Germany, September 8, 2021 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of August 2021.
The Company's preliminary, unaudited revenue from product sales in August 2021 amounted to approximately EUR 1,485 thousand, compared to EUR 1,341 thousand in August 2020, an increase of 11%.
Preliminary revenues from product sales in the US were around EUR 1,027 thousand compared to EUR 917 thousand in August 2020, an increase of 12%. In Germany, revenues from product sales amounted to approximately EUR 349 thousand, compared to EUR 345 thousand in August 2020, a slight increase of 1%. In the rest of Europe, the Company generated product sales of around EUR 109 thousand, compared to EUR 79 thousand in August 2020, a plus of 38%.
Preliminary unaudited revenues
|in EUR thousands||August2021||August2020||August2019||Jan-Aug 2021||Jan-Aug 2020||Jan-Aug 2019|
|Europe (ex Germany)||109||79||103||2,016||1,200||1,670|
|Total revenue from product sales||1,485||1,341||1,342||16,149||12,539||16,526|
|Revenues from R&D projects and license payments||0||0||48||0||6,493||323|
Due to commercial rounding, rounding differences may occur in tables.
Due to the pandemic, the monthly and year-to-date sales development is compared with sales in 2019 for increased transparency. As such, an increase of 11% in August 2021 total product sales was achieved in all markets compared to August 2019. In the USA, product sales increased by about 4% compared to August 2019. In August 2021, product sales were up by around 36% in Germany and product sales in the remaining European markets increased by approximately 7% compared to August 2019.
Compared to 2019, product sales in all markets were down by around 2% compared to sales in the period January to August 2021. Year-to-date product sales in 2021 increased by around 25% in Germany and by 21% in the rest of the European market compared to the same period in 2019. Product revenue in the US market was down 12%, mainly due to the weak sales months of January and February this year due to pandemic as well as the lack of or lower sales of Aktipak® and Xepi® compared to the period January to August 2019.
Pamela Keck, Head of Investor Relations
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.
The Germany-based company, with over 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi® for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: Nasdaq